About

Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.

Explore section

Our Strategy & Values
People

Lead Products

Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.

Explore section

Feraccru^®
Pipeline product candidates

Investors

Careers

As a unified team we are constantly driven by and committed to our goals, seeking to deliver them with transparency and respect. Being consistent to this vision, while enjoying the journey, has brought us to where we are today.

Explore section

All jobs

Interim Report for the Six Months Ended 30 June 2018

19 Sep 2018

Shield Therapeutics plc, today announces its unaudited interim results for the six months ended 30 June 2018.

For further details please see the attachment provided below.

STX_Interim report_30Jun18

Back to news

Interim Report for the Six Months Ended 30 June 2018

Sign up for news